Certara, Inc. (CERT)
| Market Cap | 896.19M -45.0% |
| Revenue (ttm) | 418.84M +8.7% |
| Net Income | -1.60M |
| EPS | -0.01 |
| Shares Out | 153.33M |
| PE Ratio | n/a |
| Forward PE | 13.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 796,852 |
| Open | 5.82 |
| Previous Close | 5.79 |
| Day's Range | 5.79 - 5.99 |
| 52-Week Range | 5.19 - 15.38 |
| Beta | 1.62 |
| Analysts | Buy |
| Price Target | 11.67 (+99.66%) |
| Earnings Date | May 11, 2026 |
About CERT
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scient... [Read more]
Financial Performance
In 2025, Certara's revenue was $418.84 million, an increase of 8.75% compared to the previous year's $385.15 million. Losses were -$1.60 million, -86.76% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CERT stock is "Buy." The 12-month stock price target is $11.67, which is an increase of 99.66% from the latest price.
News
Certara to Report First Quarter 2026 Financial Results on May 11th, 2026
RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first q...
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp® Simulator enabled physiologically-based ph...
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the followi...
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj.
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth q...
Certara Appoints Jon Resnick as Chief Executive Officer
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth
Certara Reports Third Quarter 2025 Financial Results
RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal ye...
Certara Automates Scientific Workflows with Phoenix® Cloud
RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module...
Certara Expands Biosimulation Market with AI-Driven QSP Platform
RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quanti...
Certara Scientists are Among the Topmost Cited Biopharma Researchers
RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research.
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025
RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 afte...
Final Trade: CERT, GDX, IWM, MPC
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the availability of Pinnacle 21 Enterprise Plus.
Certara Reports Second Quarter 2025 Financial Results
RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal y...
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
Certara today announced that the European Medicines Agency has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU.
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D.
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second q...
Certara Announces Expansion of Clinical Technology Collaboration with Merck
RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of...
Certara Reports First Quarter 2025 Financial Results
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal yea...
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
Certara, Inc. CERT on Monday announced expected revenue and bookings for the first quarter.
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution desig...
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologicall...